HOME > LATEST
LATEST
-
REGULATORY Epkinly, Lunsumio to Face Price Cut of 2.7% under CEA
May 15, 2025
-
BUSINESS Fujifilm Seeks Japan Nod for Stem Cell Therapy for Meniscus Injuries
May 15, 2025
-
BUSINESS Tecentriq Filed for Thymic Carcinoma in Japan: Chugai
May 15, 2025
-
REGULATORY Japan’s Parliament Enacts Bill to Amend PMD Act
May 15, 2025
-
BUSINESS Chugai’s DMD Gene Therapy Snags Conditional Approval in Japan
May 14, 2025
-
BUSINESS Sumitomo Charts Revival Plan, Eyes 250 Billion Yen with 3 Key Meds by FY2027
May 14, 2025
-
REGULATORY LDP Group Proposes Higher Cap on Social Security Budgets, Category-Based Drug Pricing
May 14, 2025
-
BUSINESS Suzuken Forms Tie-Up with Dongwon Group in South Korea
May 14, 2025
-
BUSINESS Sumitomo Pharma Logs 1st Operating Profit in 3 Years in FY2024
May 14, 2025
-
BUSINESS Mitsubishi Tanabe’s Net Profit More than Halves after Buyout Package
May 14, 2025
-
BUSINESS J-TEC’s JACC Widens Label into Knee Osteoarthritis
May 14, 2025
-
REGULATORY Health Minister Vows Cross-Ministry Response on Trump Executive Order
May 14, 2025
-
REGULATORY MHLW Official Comments on PrEP Use of HIV Drugs: Diet
May 14, 2025
-
ACADEMIA Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds
May 14, 2025
-
BUSINESS US Remains Key Market for Daiichi Sankyo: CEO
May 13, 2025
-
BUSINESS Daiichi Sankyo Pushes Global HR Revamp, Adopts Job-Based Scheme
May 13, 2025
-
BUSINESS Shionogi Nets Record Earnings for 3rd Consecutive Year on Overseas Expansion
May 13, 2025
-
REGULATORY LDP Project Team Proposes Review of Coverage Rules to Fuel Biosimilar Use
May 13, 2025
-
BUSINESS Toho Launches Specialty Drug Home Delivery Service with Vyvdura
May 13, 2025
-
REGULATORY Industry Renews Opposition to CEA Expansion at LDP Hearing
May 13, 2025
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…